Novartis AG (BCBA:NVS)

Market Cap	425.52T +105.7%
Revenue (ttm)	82.26T +9.6%
Net Income	20.30T +17.1%
EPS	10,377.51 +21.8%
Shares Out	n/a
PE Ratio	20.97
Forward PE	17.42
Dividend	624.65 (1.07%)
Ex-Dividend Date	Mar 12, 2025

Volume	18
Average Volume	148
Open	57,950
Previous Close	57,975
Day's Range	57,850 - 58,525
52-Week Range	30,425 - 58,900
Beta	n/a
RSI	67.45
Earnings Date	Feb 4, 2026

About Novartis AG

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland, the United States, China, Germany, and internationally. It focuses on developing products in cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and other therapeutic areas. The company offers Entresto, an angiotensin receptor-neprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, a...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 75,883
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: NVS

Financial Performance

In 2025, Novartis AG's revenue was $56.67 billion, an increase of 9.57% compared to the previous year's $51.72 billion. Earnings were $13.98 billion, an increase of 17.11%.

Financial numbers in USD